Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201139 | 1.00 | CYP1A2 (0.61) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| Cyanamide SCHEMBL16735391 | 0.89 | ALDH1A1 (0.51) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL12604331 | 0.88 | CYP1A2 (0.57) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL16735392 | 0.87 | ALDH1A1 (0.53) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL16181057 | 0.86 | HRH1 (0.58) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL10771160 | 0.84 | HRH1 (0.57) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL8662285 | 0.84 | CYP1A2 (0.53) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL6938906 | 0.84 | HRH1 (0.57) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL19865660 | 0.84 | CYP1A2 (0.53) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 | |
| SCHEMBL18098078 | 0.82 | CYP1A2 (0.51) | CYP1A2ALDH1A1CYP2C19HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012017242-A1 | PROCESS | BAKHU PHARMA LIMITED (GB) | 2012-02-09 | — | — | WO | claimed |
| US-4177349-A | BY-PRODUCT INHIBITION | REILLY TAR & CHEMICAL CORPORATION (US) | 1979-12-04 | — | — | US | claimed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4393920-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-1531541-A | Rhodium and iridium complexes | �����л��뵼������˾ | 2004-09-22 | — | — | CN | disclosed |
| WO-2003091388-A2 | POLYMORPHIC OLFACTORY RECEPTOR GENES AND ARRAYS, KITS AND METHODS UTILIZING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2003-11-06 | — | — | WO | disclosed |
| EP-1244453-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| EP-0725095-B1 | Process for producing a polymer of vinylic compounds | KURARAY CO (JP) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001047524-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| US-5708103-A | Process for producing a polymer of vinylic compounds | KURARAY CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0725095-A1 | Process for producing a polymer of vinylic compounds | KURARAY CO., LTD. (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-4267335-A | Substituted 2,2'-bipyridyl compounds and process for preparing same | REILLY TAR & CHEMICAL CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4177349-A | BY-PRODUCT INHIBITION | REILLY TAR & CHEMICAL CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | CYP1A2 4883/4885ALDH1A1 4262/4885CYP2C19 4877/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CYP1A2 1682/4885ALDH1A1 982/4885CYP2C19 1361/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | CYP1A2 2469/4885ALDH1A1 1238/4885CYP2C19 3666/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | CYP1A2 4669/4885ALDH1A1 4553/4885CYP2C19 4838/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | CYP1A2 4548/4885ALDH1A1 4253/4885CYP2C19 4275/4885 |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | CYP1A2 2825/4885ALDH1A1 3473/4885CYP2C19 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.